Moderna stock holds steady as pipeline expansion and positive Phase 3 results boost market sentiment

Traders Union
All News
Financial News
Moderna rises 0.64% to $35.89 today

Highlights

Moderna filed for marketing authorization of its mRNA-1010 seasonal flu vaccine in the U.S., EU, Canada, and Australia, supported by positive Phase 3 results in adults aged 50 and older.
The company is investing $140 million to expand its Norwood, Massachusetts manufacturing facility to support scaling of its mRNA vaccine pipeline and therapeutics.
Recent corporate developments include regulatory filings, U.S. approvals and label expansions for COVID-19 and RSV vaccines, and ongoing patent litigation initiated by Bayer’s Monsanto unit regarding mRNA technology.

Pipeline expansion and patent disputes shape sentiment amid vaccine filings

Moderna has filed for marketing authorization of its mRNA-1010 seasonal flu vaccine in the U.S., EU, Canada, and Australia, backed by positive Phase 3 results in adults aged 50 and older. The company is investing $140 million to expand its Norwood, Massachusetts manufacturing facility to support growth in its mRNA vaccine pipeline and therapeutics. Recent regulatory filings, U.S. approvals and label expansions for its COVID-19 and RSV vaccines, as well as ongoing patent litigation raised by Bayer’s Monsanto unit concerning mRNA technology, have also contributed to recent corporate developments.

Buyer dominance persists as overbought signals and volatility converge

Momentum signals remain favorable, with both MACD and ADX on the daily chart pointing to continued buyer pressure. RSI and Commodity Channel Index readings are elevated, reflecting overbought conditions, while the Stochastic RSI is neutral but trending high. Bull/Bear Power indicates strong buyer dominance intraday, reinforcing upward momentum. The daily session opened slightly lower than the previous close, showing a small gap down, but the price quickly rebounded and now sits near the top of today’s range, reflecting high volatility and persistent strength toward session highs.

Upside momentum seen as volatility and support consolidate scenario

The expected price range for the next five trading days is $34.00 to $38.50, reflecting recent volatility and the current trajectory. Technical signals from the weekly Moving Average, RSI, and ADX frameworks point to a high probability of further price gains, while the likelihood of a decline is currently very low (less than 20%). The baseline scenario sees MRNA consolidating sideways above $34.00. A bullish breakout above $38.50 could trigger accelerated gains, while a drop below $34.00 support risks a move back toward the $32.00 area, but momentum and trend signals currently support the upside.

Anton Kharitonov, expert at Traders Union, sees a technically bullish structure for Moderna supported by strong short- and long-term momentum. However, he remains cautious in light of elevated overbought readings and ongoing legal uncertainties. Key support is at $34.00, with resistance near $38.50, and the current trend favors consolidation unless critical levels are broken. "Until we see a confirmed breakout above $38.50 or a sustained drop below $34.00, I remain defensive and advise caution on fresh entries here."

Previously it was reported that Moderna Inc. maintained a strong bullish trend, trading well above key moving averages with momentum indicators like MACD and ADX supporting further upside, although the ADX was just below classic trend confirmation levels. However, with RSI and other oscillators signaling overbought conditions and resistance near the $36 zone, analysts caution that near-term exhaustion may develop despite sustained buyer interest.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.